07 September 2020: Clinical Research
Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy
Xianghua Zeng 123CDEG* , Shicong Zhu 12BCD* , Cheng Xu 4CF , Zhongyu Wang 12CD , Xingxing Su 12CD , Dong Zeng 12CD , Haixia Long 12AF* , Bo Zhu 12AG*DOI: 10.12659/MSM.922576
Med Sci Monit 2020; 26:e922576
Table 1 The Charlson comorbidity index weights.
| Weight | Comorbidity conditions |
|---|---|
| 1 point | History of myocardial infarction; Congestive heart failure; Peripheral disease (includes aortic aneurysm ≥6 cm); Cerebrovascular disease (with mild or no residua or transient ischemic attack); Dementia; Chronic pulmonary disease; Connective tissue disease; Peptic ulcer disease; Mild liver diseases (no portal hypertension, including chronic hepatitis); Diabetes without end-organ damage |
| 2 points | Hemiplegia; Moderate or severe renal disease; Diabetes with end-organ damage; Other tumors without metastasis (exclude if >5 years from diagnosis of non-small cell lung cancer); Leukemia (acute or chronic); Lymphoma |
| 3 points | Moderate or severe liver disease |
| 6 points | Other metastatic solid tumors (exclude if >5 years from diagnosis of non-small cell lung cancer); Acquired immunodeficiency syndrome (not just human immunodeficiency virus positive) |
| 33 points | Maximum comorbidity score |